Ginsenoside F1CAS# 53963-43-2 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 53963-43-2 | SDF | Download SDF |
PubChem ID | 9809542 | Appearance | White powder |
Formula | C36H62O9 | M.Wt | 638.88 |
Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
Synonyms | 20(S)-Ginsenoside F1 | ||
Solubility | DMSO : ≥ 100 mg/mL (156.53 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[(2S)-6-methyl-2-[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,6,12-trihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]hept-5-en-2-yl]oxyoxane-3,4,5-triol | ||
SMILES | CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CC(C4C3(CCC(C4(C)C)O)C)O)C)O)C)OC5C(C(C(C(O5)CO)O)O)O)C | ||
Standard InChIKey | XNGXWSFSJIQMNC-FIYORUNESA-N | ||
Standard InChI | InChI=1S/C36H62O9/c1-19(2)10-9-13-36(8,45-31-29(43)28(42)27(41)23(18-37)44-31)20-11-15-34(6)26(20)21(38)16-24-33(5)14-12-25(40)32(3,4)30(33)22(39)17-35(24,34)7/h10,20-31,37-43H,9,11-18H2,1-8H3/t20-,21+,22-,23+,24+,25-,26-,27+,28-,29+,30-,31-,33+,34+,35+,36-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Ginsenoside has been reported to suppress platelet aggregation and to reduce gap junction-mediated intercellular communication, also as a novel anti-skin cancer drug with anti-proliferative and anti-migration features. Ginsenoside F1 has a potential for industrial cosmetic materials, it also has inhibitory effect of elastase and tyrosinase, it significantly reduces ultraviolet-B-induced cell death by maintaining constant levels of Bcl-2 and protects HaCaT cells from apoptosis caused by ultraviolet B irradiation. |
Targets | IL Receptor | Bcl-2/Bax |
In vitro | Role of epidermal γδ T-cell-derived interleukin 13 in the skin-whitening effect of Ginsenoside F1.[Pubmed: 25091975]Exp Dermatol. 2014 Nov;23(11):860-2.Ginsenoside F1 (GF1) is a metabolite of ginsenoside Rg1. Although Ginsenoside F1 has several benefits for skin physiology, the effect of Ginsenoside F1 on skin pigmentation has not been reported. Ginsenoside F1 Modulates Cellular Responses of Skin Melanoma Cells.[Reference: WebLink]J. Ginseng Res., 2011, 35(1):86-91.Ginsenoside F1 (G-F1) is an enzymatic metabolite generated from G-Rg1. Although this metabolite has been reported to suppress platelet aggregation and to reduce gap junction-mediated intercellular communication, the modulatory activity of G-F1 on the functional role of skin-derived cells has not yet been elucidated. Inhibitory effect of elastase and tyrosinase of ginsenoside F1 isolated from Panax ginseng leaves[Reference: WebLink]Korean Journal of Pharmacognosy, 2013, 44(1):10-15.This study was carried to establish a simple isolation and purification method of Ginsenoside F1 from leaves of Panax ginseng and was to evaluate the inhibitory effect of purified Ginsenoside F1 on the activities of elastase and tyrosinase. |
Kinase Assay | Ginsenoside F1 protects human HaCaT keratinocytes from ultraviolet-B-induced apoptosis by maintaining constant levels of Bcl-2.[Pubmed: 12925222]Ginsenoside F1 attenuates hyperpigmentation in B16F10 melanoma cells by inducing dendrite retraction and activating Rho signalling.[Pubmed: 25381719]Exp Dermatol. 2015 Feb;24(2):150-2.Ginsenoside F1 (GF1) is a metabolite produced by hydrolysis of the ginsenoside Re and Rg1 in Panax ginseng. According to various studies, high amounts of ginseng components are absorbed in the metabolized form, which are key constituents responsible for the biological effects of P. ginseng. Recently, GF1 was reported to have beneficial effects on skin. However, there has not been a sound understanding of its antimelanogenic effect and underlying molecular mechanisms. J Invest Dermatol. 2003 Sep;121(3):607-13.Ginsenosides, the major active ingredients of ginseng, show a variety of biomedical efficacies such as antiaging and antioxidation. Here, we investigate the protective activity of the Ginsenoside F1, an enzymatically modified derivative of ginsenoside Rg1, against ultraviolet-B-induced damage in human HaCaT keratinocytes. |
Ginsenoside F1 Dilution Calculator
Ginsenoside F1 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.5652 mL | 7.8262 mL | 15.6524 mL | 31.3048 mL | 39.131 mL |
5 mM | 0.313 mL | 1.5652 mL | 3.1305 mL | 6.261 mL | 7.8262 mL |
10 mM | 0.1565 mL | 0.7826 mL | 1.5652 mL | 3.1305 mL | 3.9131 mL |
50 mM | 0.0313 mL | 0.1565 mL | 0.313 mL | 0.6261 mL | 0.7826 mL |
100 mM | 0.0157 mL | 0.0783 mL | 0.1565 mL | 0.313 mL | 0.3913 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Ginsenoside F1, an enzymatically modified derivative of Ginsenoside Rg1, demonstrates competitive inhibition of CYP3A4 activity and weaker inhibition of CYP2D6 activity.
In Vitro:Ginsenoside F1 has been shown to flaunt anticancer, anti-aging, and antioxidant effects and has demonstrated competitive inhibition of CYP3A4 activity and weaker inhibition of CYP2D6 activity. The cell viabilities are 68% at the highest concentration of ginsenoside F1 (200 μM) in MTT assays[1].
In Vivo:ApoE-/- mice are fed a high fat diet and orally treated with Ginsenoside F1 (50 mg/kg/day) for 8 weeks. Ginsenoside F1 treated mice significantly reduce the lesion size compared with model group mice[2].
References:
[1]. Wang DD, et al. Rare ginsenoside Ia synthesized from F1 by cloning and overexpression of the UDP-glycosyltransferase gene from Bacillus subtilis: synthesis, characterization, and in vitromelanogenesis inhibition activity in BL6B16 cells. J Ginseng Res. 2018 Jan;42(1):42-49.
[2]. Qin M, et al. Ginsenoside F1 Ameliorates Endothelial Cell Inflammatory Injury and Prevents Atherosclerosis in Mice through A20-Mediated Suppression of NF-kB Signaling. Front Pharmacol. 2017 Dec 22;8:953.
- Glycyrrhizic acid ammonium salt
Catalog No.:BCN5943
CAS No.:53956-04-0
- Aristolactam BIII
Catalog No.:BCN5718
CAS No.:53948-10-0
- Aristolactam BII
Catalog No.:BCN5717
CAS No.:53948-09-7
- Aristolactam AII
Catalog No.:BCN3924
CAS No.:53948-07-5
- Corylin
Catalog No.:BCN5716
CAS No.:53947-92-5
- Apterin
Catalog No.:BCN3910
CAS No.:53947-89-0
- Euparone
Catalog No.:BCN7204
CAS No.:53947-86-7
- Crotalarine
Catalog No.:BCN2076
CAS No.:53937-97-6
- Deoxyarbutin
Catalog No.:BCC4774
CAS No.:53936-56-4
- Hederagenin 28-O-beta-D-glucopyranosyl ester
Catalog No.:BCN1423
CAS No.:53931-25-2
- (+)-Anabasine hydrochloride
Catalog No.:BCC7219
CAS No.:53912-89-3
- Pentostatin
Catalog No.:BCC1845
CAS No.:53910-25-1
- Luteolin 7,3'-di-O-glucuronide
Catalog No.:BCN5396
CAS No.:53965-08-5
- Z-Phg-OH
Catalog No.:BCC2795
CAS No.:53990-33-3
- Cefaclor
Catalog No.:BCC2527
CAS No.:53994-73-3
- L-Nicotine
Catalog No.:BCN6269
CAS No.:54-11-5
- Tryptophan
Catalog No.:BCN2615
CAS No.:54-12-6
- 5-Hydroxyindole-3-Acetic Acid
Catalog No.:BCC8285
CAS No.:54-16-0
- Sodium salicylate
Catalog No.:BCC4846
CAS No.:54-21-7
- Furosemide
Catalog No.:BCC3782
CAS No.:54-31-9
- Metyrapone
Catalog No.:BCC7632
CAS No.:54-36-4
- Idoxuridine
Catalog No.:BCC4666
CAS No.:54-42-2
- Pilocarpine HCl
Catalog No.:BCC4702
CAS No.:54-71-7
- Cinanserin hydrochloride
Catalog No.:BCC6653
CAS No.:54-84-2
Ginsenoside F1 protects human HaCaT keratinocytes from ultraviolet-B-induced apoptosis by maintaining constant levels of Bcl-2.[Pubmed:12925222]
J Invest Dermatol. 2003 Sep;121(3):607-13.
Ginsenosides, the major active ingredients of ginseng, show a variety of biomedical efficacies such as antiaging and antioxidation. Here, we investigate the protective activity of the Ginsenoside F1, an enzymatically modified derivative of ginsenoside Rg1, against ultraviolet-B-induced damage in human HaCaT keratinocytes. Ginsenoside F1 significantly reduced ultraviolet-B-induced cell death and protected HaCaT cells from apoptosis caused by ultraviolet B irradiation. Furthermore, Ginsenoside F1 prevented ultraviolet-B-induced cleavage of poly(ADP-ribose) polymerase in HaCaT cells. In search of the molecular mechanism responsible for the antiapoptotic effect of Ginsenoside F1, we find that protection from ultraviolet-B-induced apoptosis is tightly correlated with ginsenoside-F1-mediated inhibition of ultraviolet-B-induced downregulation of Bcl-2 and Brn-3a expression.
Ginsenoside F1 attenuates hyperpigmentation in B16F10 melanoma cells by inducing dendrite retraction and activating Rho signalling.[Pubmed:25381719]
Exp Dermatol. 2015 Feb;24(2):150-2.
Ginsenoside F1 (GF1) is a metabolite produced by hydrolysis of the ginsenoside Re and Rg1 in Panax ginseng. According to various studies, high amounts of ginseng components are absorbed in the metabolized form, which are key constituents responsible for the biological effects of P. ginseng. Recently, GF1 was reported to have beneficial effects on skin. However, there has not been a sound understanding of its antimelanogenic effect and underlying molecular mechanisms. In this study, GF1 reduced alpha-melanocyte-stimulating hormone-induced melanin secretion in B16F10 cell culture media by 60%. However, it did not suppress intracellular melanin levels, tyrosinase activity and expression. Immunofluorescence assay showed that GF1 had no effect on melanosome transport, but significantly induced dendrite retraction. Pull-down assay demonstrated that GF1 primarily modulates the Rho family GTPases resulting in dendrite retraction. Collectively, these data suggest that GF1 could act as a potent skin-whitening agent.
Role of epidermal gammadelta T-cell-derived interleukin 13 in the skin-whitening effect of Ginsenoside F1.[Pubmed:25091975]
Exp Dermatol. 2014 Nov;23(11):860-2.
Ginsenoside F1 (GF1) is a metabolite of ginsenoside Rg1. Although GF1 has several benefits for skin physiology, the effect of GF1 on skin pigmentation has not been reported. We found that a cream containing 0.1% GF1 showed a significant whitening effect on artificially tanned human skin after 8 weeks of application. However, GF1 did not inhibit mRNA expression of tyrosinase or dopachrome tautomerase (DCT) in normal human epidermal melanocytes (NHEMs) or cocultured NHEMs/normal human epidermal keratinocytes. Interestingly, GF1 enhanced production of interleukin 13 (IL-13) from human epidermal gammadelta T cells. IL-13 significantly reduced the mRNA expression and protein amount of both tyrosinase and DCT and reduced melanin synthesis activities in NHEMs, resulting in visible brightening of NHEM pellet. These results suggest that enhancement of IL-13 production by GF1 from epidermal gammadelta T cells might play a role in the skin-whitening effect of GF1 via the suppression of tyrosinase and DCT.